Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 58

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 58
---
 proprietary                                   
 information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information 
 or expose us to potential litigation;                                                                                                      |

| • | partners may infringe the intellectual property rights of third parties, which may expose us to litigation 
 and potential liability; and                                                                               |

| • | agreements may be terminated and, if terminated, may result in a need for additional capital to pursue 
 further development or commercialization of the applicable product candidates.                         |

Agreements may not lead to
development or commercialization of product candidates in the most efficient manner, or at all. If any future partners of ours is involved
in a business combination, it could decide to delay, diminish or terminate the development or commercialization of any product candidate
licensed to it by us.

| 30 |

The commercial success of any of our product candidates is not guaranteed.

There can be no assurance
that any of our product candidates currently in development will be successfully developed into any commercially viable product or products
and/or be manufactured in commercial quantities at an acceptable cost or be marketed successfully and profitably. If we, or our partners,
encounter delays at any stage, and fail successfully to address such delays, it may have a material adverse effect on our business, financial
condition and prospects. In addition, our success will depend on the market’s acceptance of these products and there can be no guarantee
that this acceptance will be forthcoming or that our technologies will succeed as an alternative to competing products. If a market fails
to develop or develops more slowly than anticipated, we may be unable to recover the costs we may have incurred in the development of
particular products and may never achieve profitable royalty or licensing revenues from that product.

The pharmaceutical and biotechnology industries are highly competitive.

The development and commercialization
of new drug products is highly competitive. Our business faces competition from a range of major and specialty pharmaceutical and biotechnology
companies worldwide with respect to our product candidates, and will face competition in the future with respect to any product candidates
that we may seek to develop or commercialize.

There are a number of pharmaceutical
and biotechnology companies that currently market and sell products or are pursuing development of products that could compete with our
product candidates. With respect to eRapa, there are no currently approved products with a FAP indication, though certain non-steroidal
anti-inflammatory drugs may be prescribed off label. Panbela Therapeutics, Inc. and Recursion Pharmaceuticals, Inc. are developing products